Gavreto (Pralsetinib) Patent Expiration, LOE Window & CMS Spending
Gavreto (Pralsetinib) by Rigel Pharmaceuticals: FDA Orange Book core substance LOE 2042-07-07 (last listed 2043-04-19), 0 AB generics, $16.8M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Rigel Pharmaceuticals |
| FDA Application & Pathway | N213721 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2042-07-07 |
| Last Listed Patent or Exclusivity Date | 2043-04-19 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $16.8M |
| 2024 Medicare Part D Spend | $14.9M |
| 2024 Medicaid Spend | $1.9M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 16.9% 2-yr change) |